ANDA 206413, held by Chartwell. Temozolomide.
As of Nov 16, 2026, ANDA 206413 (Temozolomide), held by Chartwell, was first approved by FDA on Apr 12, 2016, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 12, 2016 | Original application | Approved | None posted |
| Temozolomide5MG · capsule;oral | Temozolomide | Rx |
| Temozolomide20MG · capsule;oral | Temozolomide | Rx |
| Temozolomide100MG · capsule;oral | Temozolomide | Rx |
| Temozolomide140MG · capsule;oral | Temozolomide | Rx |
| Temozolomide180MG · capsule;oral | Temozolomide | Rx |
| Temozolomide250MG · capsule;oral | Temozolomide | Rx |
| Nov 29, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Apr 12, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters